Every 10-Q that Akari Therapeutics Plc (AKTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKTX filings page.
Akari Therapeutics, Plc reported a larger net loss of $19.3 million for the six months ended June 30, 2026, compared with $5.6 million a year earlier. Results include non‑cash impairment charges of $3.7 million on AKTX‑101 IPR&D and $8.4 million on goodwill following declines in market value.
Cash and restricted cash were $7.8 million at June 30, 2026, versus $5.3 million at year-end 2025, after raising $5.2 million net in a May 2026 private placement and $3.0 million from warrant exercises. Shareholders’ equity declined to $18.6 million from $28.3 million.
Management states that existing cash is not sufficient to fund operations for 12 months, raising substantial doubt about Akari’s ability to continue as a going concern. The company entered a $25 million equity line with White Lion, increased authorized ordinary shares, and regained Nasdaq minimum bid compliance via an ADS ratio change. Akari continues to advance lead ADC candidate AKTX‑101 toward IND‑enabling work and entered a strategic preclinical collaboration with Whitehawk Therapeutics.
Akari Therapeutics reported a sharply higher quarterly loss as it wrote down key intangible assets and flagged serious liquidity pressure. For the three months ended March 31, 2026, the company recorded a net loss of $14.5 million, driven mainly by non-cash impairment charges of $3.7 million on its AKTX‑101 in‑process R&D and $8.4 million on goodwill related to the Peak Bio merger. Operating expenses rose to $15.8 million from $3.5 million a year earlier as ADC preclinical development spending increased and the impairments were recognized.
Cash and restricted cash fell to $2.8 million at March 31, 2026, with operating activities using $2.5 million of cash in the quarter. Management states this balance is insufficient to fund operations for 12 months and concludes there is “substantial doubt” about Akari’s ability to continue as a going concern, estimating existing cash funds operations only into June 2026. The company highlights an equity line with White Lion for up to $25 million, but had not drawn on it by quarter‑end. Akari remains a pre‑revenue oncology company, focused on advancing lead ADC candidate AKTX‑101 toward IND‑enabling work and a planned first‑in‑human study around mid‑2027.
Akari Therapeutics reported third-quarter 2025 results marked by a larger loss and an asset write-down. Net loss was $6.4 million for Q3 and $12.0 million for the nine months ended September 30, 2025, driven in part by a $5.18 million impairment of the PHP‑303 intangible as the company reprioritized to its ADC platform.
Cash was $2.5 million as of September 30, 2025, with an accumulated deficit of $259.3 million. Management stated these factors raise substantial doubt about the company’s ability to continue as a going concern and is evaluating financing alternatives. Total assets were $45.4 million, including $34.0 million of IPR&D (AKTX‑101), while shareholders’ equity was $22.7 million. Ordinary Shares outstanding were 71,479,461,523 as of November 13, 2025.
Akari Therapeutics, Plc reported a six-month net loss of $5.6 million and a cash and restricted cash balance of $2.7 million as of June 30, 2025. The company recorded an accumulated deficit of $252.9 million and explicitly stated that its cash balance is not sufficient to fund operations for the one-year period following issuance, which management says raises substantial doubt about the Company’s ability to continue as a going concern.
In November 2024 Akari completed the acquisition of Peak Bio, recording $39.18 million of in‑process R&D (IPR&D) and $8.43 million of goodwill tied to its ADC platform and payload PH1. During H1 2025 the company completed a March 2025 private placement with net proceeds of approximately $5.6 million and recognized a $1.2 million gain from settlement of payables. Shares outstanding increased to 65.23 billion ordinary shares at June 30, 2025, reflecting multiple financings and conversions. Subsequent events disclosed an August 2025 note purchase commitment for an aggregate purchase price of $3.0 million (aggregate principal issuable $3.8 million), expected to close in tranches.